KeyWEn.com  
 
 
 
Follow-Up       Article     History   Tree Map
  Encyclopedia of Keywords > Humans > Health > Diseases > Patients > Follow-Up   Michael Charnine

Keywords and Sections
PROGRESSION
RISK FACTORS
IMPORTANT
PHYSICIAN
COMPLETION
HELICOBACTER PYLORI
SUBJECTS
RANDOMIZED
TREATMENT PERIOD
END
TUMOR
BIOPSY
DURATION
DEATH
DEATHS
TRIAL
INTERVENTION
CASES
PROGNOSIS
BLEEDING
PEPTIC ULCER DISEASE
MEAN FOLLOW-UP PERIOD
INITIAL DIAGNOSIS
MICROSOFT TRAIN SIMULATOR
RANDOMISATION
EISENHOWER ADMINISTRATION
CONTROL GROUP
FIVE PATIENTS
EXCESSIVE DOSES
DOCTOR
DIVERTICULAR BLEEDING
HCC
SVR
CLINICAL COURSE
DISEASE RECURRENCE
PLACEBO GROUP
SIX PATIENTS
RECURRENCE
RECURRENCES
SURVIVAL
PRIMARY END POINT
SYMPTOMS
MEAN DURATION
RISK
AVERAGE FOLLOW-UP
FOLLOW-UP TEST
Review of Short Phrases and Links

    This Review contains major "Follow-Up"- related terms, short phrases and links grouped together in the form of Encyclopedia article.

Definitions

  1. Follow-up was for 3 weeks after discharge from hospital or for a maximum of 60 days from randomisation. (Web site)
  2. Follow-up is recommended every 3 to 5 years for patients with a small PDA without evidence of left-heart volume overload.
  3. Follow-up (mean 4.56 years, range 1-12 years) was completed in 25 patients; all these patients were alive and disease-free. (Web site)
  4. Follow-up is needed in cases of hepatitis B and C via blood tests, because symptoms are not a reliable sign regarding the presence of chronic infection.
  5. Follow-up was completed in all 100 patients, with a median follow-up of 24 months.

Progression

  1. Long-term follow-up evaluation of these patients is needed to detect early lymphoma relapse or progression," the authors conclude. (Web site)
  2. Follow-up studies have shown that response is durable in the majority of patients and the progression of liver lesion is stopped.

Risk Factors

  1. Long-term follow-up of patients after endoscopic sphincterotomy for choledocholithiasis, and risk factors for recurrence. (Web site)
  2. Long-term follow-up after the first episode of acute alcoholic pancreatitis: time course and risk factors for recurrence. (Web site)
  3. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. (Web site)

Important

  1. Follow-up care after treatment for colorectal cancer is very important.
  2. Blood tests can measure HCG levels; these tests are important in diagnosis, staging, and in follow-up of some testicular cancers.
  3. The treatment of arrhythmias has improved in recent years, so it's important you seek appropriate follow-up care. (Web site)

Physician

  1. Arrangements will be made for a follow-up visit with your physician, usually two to three weeks after the procedure.
  2. A physician can adjust the intensity, duration and frequency of the stimulation, which may be minimally noticeable by the patient, in follow-up visits. (Web site)
  3. Any nodule not removed needs to be watched closely with an examination and follow-up with the physician every 6-12 months.

Completion

  1. Follow-up after completion of treatment was monthly with physical examination and CA125, with radiological investigations as indicated by these findings. (Web site)
  2. The American Society of Clinical Oncology (ASCO) sets guidelines for follow-up testing to detect recurring cancer after the completion of treatment. (Web site)
  3. Patients returned for follow-up visits 3, 6, 9, and 12 months after completion of the medication. (Web site)

Helicobacter Pylori

  1. Recurrence of duodenal ulcers during five years of follow-up after cure of Helicobacter pylori infection. (Web site)
  2. Long-term follow-up after eradication of Helicobacter pylori with a combination of omeprazole and amoxycillin. (Web site)
  3. Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood. (Web site)

Subjects

  1. Follow-up documented cancer or adenoma in 83% of subjects when the polyp or mass seen during sigmoidoscopy was a centimeter or larger.
  2. HPV infections in 3 subjects with multiple subsequent infections during long-term follow-up: HPV DNA testing and typing along the time scale.
  3. Among subjects on whom follow-up data could be obtained, the median lag time between observations at T1 and T2 was 8.8 yr, and between T2 and T3 was 6.4 yr. (Web site)

Randomized

  1. DESIGN: Follow-up of up to 2 years in patients with healed ulcers who had participated in randomized, controlled trials. (Web site)
  2. This was a randomized, controlled, single-blind trial with 3 months of follow-up in a primary care, inner-city health center. (Web site)
  3. Fifty-five patients were randomized and 38 completed at least 1 year of follow-up. (Web site)

Treatment Period

  1. Concomitant medication will be documented at screening and baseline, visit 11 at the end of the treatment period as well as at each follow-up visit.

End

  1. Patients were considered lost to follow-up if they had not been seen at a visit within one year before the end of the study.
  2. Follow-up averaged 4.1 years; 82% of those assigned to hormone treatment were taking it at the end of 1 year, and 75% at the end of 3 years.
  3. At the end of the treatment period, patients are followed for a 2-week period of follow-up. (Web site)

Tumor

  1. Follow-up care for a pituitary gland tumor may include tests to measure hormone levels and MRI scans to learn how the tumor responded to treatment. (Web site)
  2. Results: The tumor was treated by surgical excision, with no additional treatment, other than follow-up. (Web site)
  3. At a median follow-up of 3 years, 10 of 93 patients had died, all but 1 from a second (solid) tumor. (Web site)

Biopsy

  1. During your follow-up visit, your doctor will discuss the results of your biopsy with you and take out your stitches. (Web site)
  2. A follow-up liver biopsy was performed 0.5–5.5 years (mean ± SD, 1.9 ± 1.4 years) after end of treatment in 51 patients.
  3. Follow-up scans for three patients showed close correlation of 67Ga uptake with myocarditis on biopsy. (Web site)

Duration

  1. Duration of treatment and follow-up was 18 months.
  2. Duration of endoscopic follow-up was 6 years and follow-up based on serum levels of pepsinogen I and antibodies to H. pylori covered a period of 10 years. (Web site)
  3. Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. (Web site)

Death

  1. Those with elevated cTnT levels (defined by the 99th percentile cut-off value) had an increased risk of death after 1, 2 and 3 years of follow-up.
  2. Participants free of hepatocellular carcinoma at their death or at the end of follow-up were censored. (Web site)
  3. After an average follow-up period of 5.4 years, the risk of death from all causes in patients older than 65 who received simvastatin was reduced by 34%. (Web site)

Deaths

  1. Liver cancer was diagnosed post mortem in 5 patients during a follow-up study of deaths among the 215 patients who had dropped out.
  2. Four patients died during follow-up; 2 of these deaths were related to multiple endocrine neoplasia.
  3. The last follow-up of this cohort found that only 37 mesothelioma deaths had been identified among 8,000 deaths from all causes (McDonald et al., 1993). (Web site)

Trial

  1. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial.
  2. Unilateral versus bilateral neck exploration for primary hyperparathyroidism: five-year follow-up of a randomized controlled trial.
  3. Nevertheless, the event rate in the trial was low (60% of that originally predicted), requiring the authors to extend follow-up from 5.0 to 9.5 years.

Intervention

  1. Patients rated nasal disease-specific symptoms and completed a self-administered quality of well-being questionnaire before intervention and at follow-up. (Web site)
  2. Despite these dietary changes, there was no evidence that the intervention reduced the risk of invasive colorectal cancer during the follow-up period.
  3. Clinical examination was performed at selection (visit 0, V0), inclusion (V1), follow-up (V2, week 4) and end of intervention (V3, week 8).

Cases

  1. Long-term follow-up studies of patients with suspected viral myocarditis reveal progression to dilated cardiomyopathy (DCM) in a significant number of cases. (Web site)
  2. In addition, it recommends that in cases where antibiotics are not prescribed in these patients, close follow-up must be ensured.
  3. Patients treated on an out-of-hospital basis had no serious complications after a mean follow-up of 38 months (no cases of cardiac tamponade).

Prognosis

  1. They can be used to stage cancer, to indicate a prognosis, to monitor treatment, or in follow-up to watch for cancer recurrence. (Web site)
  2. METHODOLOGY: All 110 patients were treated for their esophageal varices and their prognosis and complications were analyzed during the follow-up period.
  3. In the Rai staging system, with long-term follow-up, it appears that stage IV patients have a slightly better prognosis than Rai stage III patients.

Bleeding

  1. In trials that compared inpatient and outpatient treatment, the rates of recurrent DVT, major bleeding, and death during follow-up differed only slightly.
  2. The study outcome was the composite of recurrent venous thromboembolism and major bleeding during an average follow-up of 1.4 years.

Peptic Ulcer Disease

  1. At the long-term follow-up of successful eradication cases, 89.8% of the patients were free of peptic ulcer disease. (Web site)

Mean Follow-Up Period

  1. Results: During a mean follow-up period of 95 months, 8 patients died, 9 underwent reoperation, and 12 received catheter intervention. (Web site)
  2. During a mean follow-up period of 24 months, 18 patients died of cardiopulmonary causes. (Web site)

Initial Diagnosis

  1. Detection of colorectal tumor and inflammatory bowel disease during follow-up of patients with initial diagnosis of irritable bowel syndrome.
  2. The mean follow-up period after initial diagnosis was 22 months (range, 6 months–6 years). (Web site)

Microsoft Train Simulator

  1. Microsoft Train Simulator 2, the follow-up to the number one best-selling train simulation PC game, will be available in stores around Christmas time. (Web site)

Randomisation

  1. Taking into account a dropout rate of 25% between randomisation and end of follow-up, this would require 128 patients in each study group. (Web site)

Eisenhower Administration

  1. The Apollo program was originally conceived early in 1960, during the Eisenhower administration, as a follow-up to America's Mercury program. (Web site)

Control Group

  1. Long-term follow-up after hospital discharge was incomplete with 10 patients missing in the treatment and 7 patients in the control group. (Web site)
  2. The mean follow-up period was 2.7 years in the lamivudine group and 5.3 years in the control group. (Web site)
  3. Male circumcision was offered to the intervention group immediately after randomization and to the control group at the end of the follow-up. (Web site)

Five Patients

  1. In five patients with a follow-up between 56 months and 101 months, the last MC amplification was sequenced and compared with the original lymphoma sample. (Web site)
  2. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. (Web site)
  3. All five patients are currently alive without evidence of tumor recurrence after a median follow-up of 43 months.

Excessive Doses

  1. Excessive doses of thyroid hormones frequently go undetected due to the lack of follow-up of patients taking their thyroid medicine. (Web site)

Doctor

  1. After treatment for a pituitary gland tumor ends, talk with your doctor about developing a follow-up care plan.
  2. Once you have finished with your examination, you may resume normal activity; you need to follow-up with your doctor a few days after the examination. (Web site)
  3. You should follow-up with your doctor as recommended and regularly examine your skin once a month, using a mirror to check hard-to-see places. (Web site)

Diverticular Bleeding

  1. Results During 18 years of follow-up, there were 801 incident cases of diverticulitis and 383 incident cases of diverticular bleeding. (Web site)
  2. During 18 years of follow-up, there were 801 new cases of diverticulitis and 383 new cases of diverticular bleeding.
  3. During 18 years of follow-up, researchers identified 383 cases of diverticular bleeding and 801 cases of diverticulitis. (Web site)

Hcc

  1. To our knowledge, there are no reports about incidences of HCC that selected only patients who seroconverted to anti-HBe during follow-up. (Web site)
  2. During the long-term follow-up, 4 patients with cirrhosis developed hepatocellular carcinoma (HCC), which was discovered by ultrasound examination.
  3. Liver nodules were found in 43 patients, 11 of whom had HCC. Cumulative incidence of HCC during follow-up was 4%. (Web site)

Svr

  1. Our report highlights the need for careful follow-up for more than 10 years even if the patients with CH-C achieve SVR to IFN therapy. (Web site)
  2. After 6 months of follow-up 5 patients on mono and 10 patients on combo maintained a sustained virological response (SVR: 9.8% vs 19.6%, p=ns). (Web site)
  3. During the follow-up period, reappearance of serum HCV RNA was found in one patient, who has achieved SVR in 6-MU group, at the 57th month.

Clinical Course

  1. Five years after treatment, 108 patients (81% of the initial group) were available for the follow-up of the clinical course of peptic ulcer.
  2. Clinical course and long-term follow-up in patients without clinically overt heart disease. (Web site)
  3. Allergic eosinophilic gastroenteritis with protein-losing enteropathy: intestinal pathology, clinical course, and long-term follow-up.

Disease Recurrence

  1. All patients had radiologic investigations at follow-up to exclude disease recurrence. (Web site)
  2. Liver transplantation for alcoholic cirrhosis: long term follow-up and impact of disease recurrence.
  3. This can help reduce the risk of disease recurrence and facilitate follow-up monitoring. (Web site)

Placebo Group

  1. Eleven patients (three in the trandolapril group and eight in the placebo group) received study medication but did not return for a follow-up visit.
  2. This was contrary to protocol and biased the study against EDTA. Wide variability made follow-up testing of the placebo group almost totally unreliable.
  3. Follow-up endoscopy revealed similar rates of ulcer healing in the treatment and placebo group (84.7% and 92.8%, respectively; p=0.14). (Web site)

Six Patients

  1. Six patients did not consistently wear their patches on each day in this 3-day period, and 1 patient did not return for follow-up at week 4.
  2. None of the six patients with IA who underwent pacemaker implantation had recurrence of asystolic events during mean follow-up of 5 years.
  3. Five of the six patients are still in clinical remission after a median follow-up period of 5 months. (Web site)

Recurrence

  1. Follow-up care to assess the results of treatment and to check for recurrence is very important. (Web site)
  2. Trials of the prevention of recurrence were included only if patients who had had gout and had at least 6 months of follow-up were studied.
  3. Surgery followed by chemotherapy for patients at high risk of recurrence, with lifelong follow-up.

Recurrences

  1. Results. Seventeen (25%) patients had recurrences of acute alcoholic pancreatitis during the follow-up.
  2. A benign biologic behavior has been suggested based on the absence of recurrences with a median follow-up of 3 years.
  3. Mean follow-up time has been 18 months, and to date no recurrences at the site of resection or port-site metastases have been observed.

Survival

  1. Each implant was categorized as "survival" or "failure" after 1 to 4 years of follow-up after prosthesis implantation. (Web site)
  2. Patients had a median follow-up of 39 months and 79% of the patients were followed at least 12 months for survival and selected adverse events. (Web site)
  3. Long-term follow-up of patients with suspected deep vein thrombosis of the upper extremity: survival, risk factors and post-thrombotic syndrome. (Web site)

Primary End Point

  1. The primary end point was a sustained virologic response (defined as a serum HCV RNA level below 50 IU per milliliter at the end of follow-up, at week 72). (Web site)
  2. During follow-up, 22% of the patients (n=40) reached the primary end point. (Web site)
  3. The primary end point was the average Izbicki pain score during 2 years of follow-up.

Symptoms

  1. During follow-up (median 24 months, range 18 to 24 months), there was no recurrence of symptoms (bleeding, tenesmus). (Web site)
  2. The remaining two patients have also showed progressive improvement in their symptoms following surgery for 4 years on follow-up. (Web site)
  3. Endoscopy was carried out at the end of the follow-up or whenever symptoms appeared.

Mean Duration

  1. The mean duration of follow-up was 3.2 years.
  2. RESULTS: The mean duration of follow-up was 40 months. (Web site)

Risk

  1. After treatment for oropharyngeal cancer, frequent and careful follow-up is important because of the risk of developing a second cancer in the head or neck.
  2. Laparoscopic cholecystectomy is recommended as definitive treatment for patients whose risk for general anesthesia improves in follow-up.
  3. This fact could facilitate the identification of patients at risk and improved care during follow-up of these patients.

Average Follow-Up

  1. RESULTS: Average follow-up of the 3640 enrolled study participants, aged 55-80 years, was 6.3 years, with 2.4% lost to follow-up. (Web site)
  2. The patients subsequently underwent periodic colonoscopy during an average follow-up of 5.9 years, and the incidence of colorectal cancer was ascertained.
  3. At an average follow-up of 27.8 months, 80 of the patients were disease free. (Web site)

Follow-Up Test

  1. It may be done as a follow-up test after treatment for an abnormal Pap test. (Web site)
  2. Colonoscopy also is used as a follow-up test if anything unusual is found during one of the other screening tests. (Web site)
  3. Also covers high-risk patients every two years and those needing a follow-up test after FOBT or Flex Sig.

Categories

  1. Humans > Health > Diseases > Patients
  2. Encyclopedia of Keywords > Time > Calendars > Months
  3. Health > Diseases > Treatments > Treatment
  4. Encyclopedia of Keywords > Time > Years
  5. Study

Related Keywords

    * Baseline * Cohort * Colonoscopy * Colorectal * Complications * Diagnosis * Evaluation * Examination * Follow-Up Appointment * Follow-Up Appointments * Follow-Up Colonoscopy * Follow-Up Data * Follow-Up Evaluation * Follow-Up Study * Follow-Up Testing * Follow-Up Treatment * Follow-Up Visits * Hepatitis * Hepatocellular Carcinoma * Incidence * Mean * Mean Follow-Up * Median * Median Duration * Median Follow-Up * Monitor * Months * Mortality * Outcome * Participants * Patient * Patients * Placebo * Procedure * Pylori * Results * Screening * Study * Therapy * Three Patients * Transplantation * Treatment * Weeks * Year * Years * Years Follow-Up
  1. Books about "Follow-Up" in Amazon.com

Book: Keywen Category Structure


  Short phrases about "Follow-Up"
  Originally created: April 04, 2011.
  Links checked: February 07, 2013.
  Please send us comments and questions by this Online Form
  Please click on Move Up to move good phrases up.
0.0279 sec. a=1..